Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

NPS+ Melanoma (EU5)

Product Code:
596200712
Publication Date:
May 2016
Format:
PDF
Price:
€2495

One brand is gaining ground in Europe – but who is coming a close second?

When making melanoma treatment choices, are EU oncologists favouring particular brands? Oncologists claim to be broadly satisfied with the range of treatments available, however they are also happy to recommend more than one option. Why? It there an opportunity for one brand to build loyalty over the rest?

FirstView’s NPS+ Melanoma report assesses the brand health of 7 melanoma treatments. See exactly how your brand is performing and get the insight you need to build a targeted brand strategy and improve your market share.

Interested in the US market? Click here to see the US Edition.

 Request Sample Pages

Get Answers to Key Questions About Melanoma Treatments

  • Opdivo (nivolumab, BMS): Which two drugs are the majority of Opdivo Promoters also recommending? Could they be persuaded to stay more loyal to Opdivo?
  • Keytruda (pembrolizumab, MSD): Which brand message is top of the list for EU oncologists, yet is not getting through to their US counterparts?
  • Yervoy (ipilimumab, BMS): Market share amongst Promoters looks healthy but what does the Yervoy loyalty score reveal about the likelihood of switching?
  • Zelboraf (vemurafenib, Roche): Promoters of Zelboraf strongly favour one other brand – which one?
  • Mekinist (trametinib, Novartis): Do EU oncologists view Mekinist and Tafinlar as interchangeable?
  • Tafinlar (dabrafenib, GSK): What does Tafinlar’s brand DNA show about how EU oncologists view it within the treatment paradigm?
  • Proleukin (aldesleukin, Prometheus): Which top three brand messages are strongest amongst Promoters? Could these be the key to taking on the two competitor brands leading the field?

Top Takeaways

  • One brand is healthiest by far: Although all but one of the brands surveyed showed a positive NPS, the leader showed a 31% improvement on second place in the US and a 41% improvement in Europe.
  • Loyalty is relatively low: 3-4 other choices are actively considered for all brands except one – find out which one.
  • One brand has a huge opportunity to gain market share: If its Detractors can be converted into Promoters, this brand stands to gain significantly more than any other surveyed.
  • One key message dominates: Of all the drugs surveyed, one brand message consistently ranked in the top three. Find out which one.

Explore Important Brand Loyalty Issues

NPS+ Melanoma (US) explores key issues affecting brand loyalty for melanoma drug manufacturers. You’ll learn:

  • How satisfied the melanoma market is.
  • How loyal doctors are to your brand.
  • How many other brands your Promoters recommend.
  • Which other brands your Promoters and Detractors recommend.
  • How much market share your brand has among Promoters and Detractors.
  • How much market share you stand to gain by converting Detractors into Promoters.
  • Which messages Promoters, Passives and Detractors associate with your brand.
  • Your brand DNA: what doctors really think of your brand—in their own words.

A Report Based on Expert Knowledge

We surveyed 150 Medical Oncologists from the EU5 (France, Italy, Germany, Spain, UK), chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between the 12th and 17th May 2016.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.

How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Request Sample Pages

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Request Sample Pages




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved